江苏浩欧博生物医药股份有限公司关于为董事、监事及高级管理人员购买责任保险的公告

Group 1 - The company plans to purchase liability insurance for its directors, supervisors, and senior management to protect investor interests and reduce operational risks [1][26] - The insurance coverage limit is set at a maximum of RMB 50 million, with an annual premium not exceeding RMB 250,000 [1] - The decision to purchase insurance will be submitted for approval at the upcoming extraordinary general meeting of shareholders scheduled for September 25, 2025 [1][3] Group 2 - The extraordinary general meeting will be held on September 25, 2025, at 10:00 AM in the company's conference room [4] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's online voting system [4][6] - Shareholders must register for the meeting by September 24, 2025, and can delegate their voting rights to a proxy [10][15] Group 3 - The company has recently completed the cancellation of its special account for raised funds, as the related project has concluded [21][22] - The total amount raised from the initial public offering was RMB 555.86 million, with a net amount of RMB 496.47 million after deducting issuance costs [21] - The funds from the special account have been fully utilized, and the remaining interest of RMB 96.84 has been transferred to the company's main account [22]